Cite
HARVARD Citation
Ma, B. et al. (2013). Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first‐line treatment of metastatic colorectal cancer. Cancer. 119 (23), pp. 4145-4153. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ma, B. et al. (2013). Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first‐line treatment of metastatic colorectal cancer. Cancer. 119 (23), pp. 4145-4153. [Online].